FR3088541B1 - Procede de conservation de cellules a visee therapeutique - Google Patents

Procede de conservation de cellules a visee therapeutique Download PDF

Info

Publication number
FR3088541B1
FR3088541B1 FR1860544A FR1860544A FR3088541B1 FR 3088541 B1 FR3088541 B1 FR 3088541B1 FR 1860544 A FR1860544 A FR 1860544A FR 1860544 A FR1860544 A FR 1860544A FR 3088541 B1 FR3088541 B1 FR 3088541B1
Authority
FR
France
Prior art keywords
conservation process
cells
composition
therapeutic purposes
therapeutic aims
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR1860544A
Other languages
English (en)
Other versions
FR3088541A1 (fr
Inventor
Larichaudy Joffrey De
Nemorin Sandy Cazalon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LFB SA
Original Assignee
LFB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LFB SA filed Critical LFB SA
Priority to FR1860544A priority Critical patent/FR3088541B1/fr
Priority to PCT/EP2019/081339 priority patent/WO2020099571A1/fr
Priority to EP19801368.2A priority patent/EP3880167A1/fr
Priority to US17/293,867 priority patent/US20220226383A1/en
Publication of FR3088541A1 publication Critical patent/FR3088541A1/fr
Application granted granted Critical
Publication of FR3088541B1 publication Critical patent/FR3088541B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Botany (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention se rapporte à une composition comprenant, dans un milieu physiologiquement acceptable : a) au moins un saccharide, b) au moins une vitamine, c) au moins un acide aminé, d) au moins un antioxydant, et e) des cellules à visée thérapeutique, ladite composition ayant un pH compris entre 7.0 et 8.5, de préférence entre 7.0 et 8.3. Elle se rapporte également à un procédé de conservation d'un échantillon de cellules à visée thérapeutique, comprenant au moins une étape de mélange de l'échantillon de cellules à visée thérapeutique avec les ingrédients a) à d) ci-dessus et un milieu physiologiquement acceptable, la composition ainsi obtenue ayant un pH compris entre 7.0 et 8.5, de préférence compris entre 7.0 et 8.3.
FR1860544A 2018-11-15 2018-11-15 Procede de conservation de cellules a visee therapeutique Expired - Fee Related FR3088541B1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
FR1860544A FR3088541B1 (fr) 2018-11-15 2018-11-15 Procede de conservation de cellules a visee therapeutique
PCT/EP2019/081339 WO2020099571A1 (fr) 2018-11-15 2019-11-14 Procédé de conservation de cellules à visée thérapeutique
EP19801368.2A EP3880167A1 (fr) 2018-11-15 2019-11-14 Procédé de conservation de cellules à visée thérapeutique
US17/293,867 US20220226383A1 (en) 2018-11-15 2019-11-14 Method of preserving cells for therapeutic use

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1860544A FR3088541B1 (fr) 2018-11-15 2018-11-15 Procede de conservation de cellules a visee therapeutique

Publications (2)

Publication Number Publication Date
FR3088541A1 FR3088541A1 (fr) 2020-05-22
FR3088541B1 true FR3088541B1 (fr) 2021-11-05

Family

ID=65763602

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1860544A Expired - Fee Related FR3088541B1 (fr) 2018-11-15 2018-11-15 Procede de conservation de cellules a visee therapeutique

Country Status (4)

Country Link
US (1) US20220226383A1 (fr)
EP (1) EP3880167A1 (fr)
FR (1) FR3088541B1 (fr)
WO (1) WO2020099571A1 (fr)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5543316A (en) * 1994-04-20 1996-08-06 Diacrin, Inc. Injectable culture medium for maintaining viability of myoblast cells
US6485959B1 (en) * 1998-10-07 2002-11-26 Cedars Sinai Medical Center Cell preconditioning and cryopresevation medium
FR2810045B1 (fr) 2000-06-07 2004-09-03 Assist Publ Hopitaux De Paris Procede d'obtention de population cellulaires caracterisees d'origine musculaire et utilisations
KR101718375B1 (ko) * 2007-12-04 2017-03-22 프로테오바이오엑티브스 피티와이 엘티디 전구 세포의 보호 및 그의 분화 조절
WO2014208053A1 (fr) * 2013-06-28 2014-12-31 株式会社大塚製薬工場 Solution contenant un tréhalose et un dextrane pour la transplantation de cellules de mammifères
FR3040396A1 (fr) * 2015-06-30 2017-03-03 Chu Nantes Procede de cryoconservation de lymphocytes infiltrant la tumeur
FR3040860B1 (fr) * 2015-09-10 2020-05-15 Universite de Bordeaux Milieu de conservation injectable pour la conservation de cellules du sang placentaire, de la moelle osseuse et du sang peripherique

Also Published As

Publication number Publication date
US20220226383A1 (en) 2022-07-21
FR3088541A1 (fr) 2020-05-22
EP3880167A1 (fr) 2021-09-22
WO2020099571A1 (fr) 2020-05-22

Similar Documents

Publication Publication Date Title
ES2676600T3 (es) Fabricación y uso de ARN monocatenario sintetizado in vitro para la introducción en células de mamífero para inducir un efecto biológico o bioquímico
BRPI0611535A8 (pt) Métodos para processar células de microorganismos e células de levedura, composição, suplemento alimentar, produto farmacêutico, cosmético ou produto nutracêutico e ração animal
FR3057141B1 (fr) Formulation de gel de cellules souches pour maintenir la viabilite de cellules cryoconservees et son utilisation
CR6026A (es) Preparaciones farmaceuticas estabilizadas de gabapentina y proceso para prepararla
TN2010000239A1 (fr) Composition pour l'alimentation humaine et/ou animale ses utilisations, levures
FR3067928B1 (fr) Procede de conservation d'un echantillon de bacteries
CN106727097A (zh) 一种具有强效广谱抑菌活性的天然化妆品防腐组合物
PH12020551057A1 (en) Group b adenovirus-containing formulation
FR3064269B1 (fr) Procede de preparation d'un extrait liquide de phycobiliproteines, en particulier de phycocyanine, a partir de cyanobacteries ou de microalgues et extrait ainsi obtenu
CL2022001655A1 (es) Variantes diseñadas de la alfa-glucosidasa ácida.
FR3074018B1 (fr) Procede de cryoconservation de cellules a visee therapeutique
CL2022001035A1 (es) Composiciones y métodos para minimizar la pérdida de proteínas a concentraciones de proteínas bajas
MA29351B1 (fr) Composition de spirulines riche en principes actifs, son procede d'obtention et son utilisation
FR3088541B1 (fr) Procede de conservation de cellules a visee therapeutique
Souza dos Santos et al. Characterization of proteinases in Herpetomonas anglusteri and Herpetomonas roitmani
TW201832775A (zh) 茶樹癒傷組織萃取物於護膚之用途
BR112022003639A8 (pt) Agente bioestimulante para tratamento de plantas e/ou de sementes de plantas
PH12019500738A1 (en) Methods of preserving the biological activity of ribonucleic acids
FR3034662B1 (fr) Nouvelles utilisations du peptide de sequence his-d-trp-ala-trp-d-phe-lys-nh2 pour diminuer ou retarder l'apparition de la senescence cellulaire et des signes du vieillissement cutane
ATE537702T1 (de) Flüssiges teigverbesserungsmittel
Hasan et al. The effect of Chlorella vulgaris salep extract on the formation of bone remodeling
JP5797902B2 (ja) グルタチオン産生促進剤
Johnson et al. The amino acid requirements of Microsporum fulvum
FR3120310B1 (fr) Shampoing
FR3112488B1 (fr) Utilisation d’un extrait de Codium fragile riche en arabinogalactanes sulfatés dans des compositions cosmétiques anti-âge.

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20200522

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

CA Change of address

Effective date: 20221108

PLFP Fee payment

Year of fee payment: 6

ST Notification of lapse

Effective date: 20250705